Cooperative Agreement U01FD007803

Award Date 9/15/22
Completion Date 8/31/25
Dollars Obligated $4.1M
Federal Grant Program
93.103
Assistance Type
Cooperative Agreement
Place of Performance
Michigan, USA
Similar Awards
This Project Grant award by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to improve perioperative care for patients with opioid use disorder. The total award of $779,969 will be used to: Prospectively capture patient-reported pain and opioid use data among individuals with opioid use disorder undergoing common surgical procedures, to inform the adaptation of prescribing guidelines. Qualitatively assess the...
This federal Project Grant award for $701,959, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to improve perioperative care for patients with opioid tolerance. The key objectives are to: Prospectively capture patient-reported opioid use and pain outcomes among opioid tolerant individuals undergoing common surgical procedures, and develop a clinical care pathway to optimize outcomes across a network of hospitals in...
This federal Project Grant award in the amount of $945,397, awarded by the National Institute on Drug Abuse under CFDA 93.279 "Drug Use and Addiction Research Programs", supports research to adapt and evaluate the impact of a collaborative care model (CCM) for pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt an existing CCM for rural and low-resource obstetric settings, 2) create a common data model to harmonize...
This $1,999,999 Cooperative Agreement awarded by the Center for Drug Evaluation and Research (CDER), part of the U.S. Food and Drug Administration (CFDA 93.103 Food and Drug Administration Research), will support the development, dissemination, and evaluation of an evidence-based clinical practice guideline for managing perioperative pain associated with abdominal laparoscopic surgeries. The project, titled "Managing Perioperative Pain with Abdominal Laparoscopic Surgery: A Collaborative to...
This $6,809,660 Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke, under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to implement and investigate the efficacy and safety of a methadone-based standardized enhanced recovery after surgery (ERAS) protocol, as well as develop personalized ERAS protocols including precision methadone and oxycodone dosing, for the opioid-sparing management of surgical pain in children undergoing...
This Project Grant award from the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program provides $398,972 in funding to the University of California, Davis to conduct a 5-year mixed-methods study (September 2024 - June 2029) on improving hospital care practices for newborns with prenatal substance exposure. The study aims to: 1) survey hospitals in the BORN nationwide research network to delineate current care...
This federal Project Grant award from the National Institutes of Health (CFDA 93.279 - Drug Abuse and Addiction Research Programs) provides $1,105,489 to The Leland Stanford Junior University (Stanford University) to fund research aimed at reducing the risk of persistent postoperative opioid use and opioid use disorder among older adults undergoing inpatient surgery. The key products and services to be delivered under this 2-year grant include: Augmenting an existing dataset that links...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...
This federal Project Grant award of $1,499,606.00 from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to characterize health outcomes and identify disparities in children born to people with opioid use disorder (OUD) from birth to 5 years of age. The study will utilize data from the Texas Neonatal Care Research Collaborative to: Examine variation in the diagnosis of neonatal opioid withdrawal syndrome (NOWS) across hospitals and identify...

CLINICAL PRACTICE GUIDELINES FOR POSTOPERATIVE PAIN IN PREGNANCY: EVIDENCE, DISSEMINATION, AND IMPACT - PROJECT SUMMARY OVER 4 MILLION BIRTHS OCCUR IN THE UNITED STATES EACH YEAR, AND OPIOID PRESCRIBING FOR ACUTE PAIN DURING PREGNANCY AND CHILDBIRTH IS COMMON AND HIGHLY VARIABLE. GUIDELINES TO DIRECT OPIOID PRESCRIBING DURING PREGNANCY AND BIRTH ARE SPARSE, LEADING TO EXCESSIVE PRESCRIBING AND INCREASING THE RISK OF OPIOID OVERDOSE, ADDICTION, DIVERSION, AND PERSISTENT OPIOID USE. IN THIS 3 YEAR STUDY, WE WILL CREATE EVIDENCE-BASED, PATIENT- CENTERED GUIDELINES TO SUPPORT ACUTE POSTOPERATIVE PAIN MANAGEMENT FOR PREGNANT INDIVIDUALS DURING CHILDBIRTH AND SURGERY. WE WILL EXAMINE THE EFFECTIVENESS OF IMPLEMENTING THESE GUIDELINES ON CLINICAL AND PATIENT- REPORTED OUTCOMES IN A LARGE, STATE-WIDE CONSORTIUM OF 68 HOSPITALS WITHIN THE COLLABORATIVE QUALITY IMPROVEMENT PROGRAMS IN MICHIGAN. WE WILL CONVENE A NATIONAL PANEL OF PATIENTS, PROVIDERS, REPRODUCTIVE JUSTICE ADVOCATES, HEALTH EQUITY EXPERTS, AND HEALTH SYSTEM LEADERS TO GUIDE ALL ACTIVITIES. FIRST, WE WILL USE THE RAND/UCLA APPROPRIATENESS METHODOLOGY TO MERGE A SYSTEMATIC LITERATURE REVIEW WITH EXPERT OPINION TO CREATE PROVIDER- AND PATIENT-FACING GUIDELINES THAT DIRECT OPIOID PRESCRIBING, INTEGRATE OPIOID-ALTERNATIVES AND CONSIDERATIONS FOR UNIQUE POPULATIONS (HIGH-RISK PREGNANCIES, COMORBID CONDITIONS, PRIOR OPIOID EXPOSURE, OPIOID AND SUBSTANCE USE DISORDERS), AND INCLUDE BEST PRACTICES TO PROMOTE HEALTH EQUITY AND PATIENT- CENTEREDNESS (PHASE 1). WE WILL CREATE TAILORED STRATEGIES FOR CPG DISSEMINATION AND IMPLEMENTATION USING STATE OF THE ART TECHNIQUES IN IMPLEMENTATION SCIENCE AT THE NATIONAL AND FACILITY LEVEL (PHASE 2). FINALLY, WE WILL CONDUCT AN ENHANCED, NON-RESPONDER RANDOMIZED TRIAL ACROSS 68 HOSPITALS IN MICHIGAN TO DETERMINE THE EFFECTIVENESS OF CPGS THAT INFORM OPIOID PRESCRIBING DURING PERIPARTUM CARE AS WELL AS THE IMPACT OF INNOVATIVE, ADAPTIVE IMPLEMENTATION INTERVENTIONS AT THE HOSPITAL LEVEL (PHASE 3). OUR PRIMARY OUTCOMES WILL INCLUDE THE RATE AND AMOUNT OF OPIOID PRESCRIBED AMONG PREGNANT INDIVIDUALS DURING SURGERY AND CHILDBIRTH. WE WILL ALSO EXAMINE PATIENT-REPORTED OUTCOMES (E.G., POSTOPERATIVE PAIN, OPIOID USE, SATISFACTION) AS SECONDARY OUTCOMES. WE WILL SPECIFICALLY EXAMINE THE EFFECT OF CPGS ACROSS MARGINALIZED GROUPS TO ENSURE THAT GUIDELINE IMPLEMENTATION DOES NOT EXACERBATE EXISTING DISPARITIES IN POSTOPERATIVE PAIN MANAGEMENT. OUR FINDINGS WILL DIRECTLY IMPACT OBSTETRIC CARE BY RIGOROUSLY CREATING PRAGMATIC, PATIENT-CENTERED GUIDELINES TO DIRECT POSTOPERATIVE OPIOID PRESCRIBING THAT ARE TAILORED TO THE UNIQUE NEEDS OF PREGNANT AND BIRTHING INDIVIDUALS. GIVEN THE ROBUST NETWORK OF COLLABORATIVE HOSPITAL SYSTEMS CARING FOR A DIVERSE COHORT OF PREGNANT INDIVIDUALS IN MICHIGAN, OUR FINDINGS WILL PROVIDE CRITICAL EVIDENCE TO DIRECT OPTIMAL STRATEGIES FOR GUIDELINE DISSEMINATION AND IMPLEMENTATION ACROSS THE UNITED STATES.

Posted 9/15/22, 12:00 AM